CareDx upgraded to Outperform with $12 target at Raymond James

Raymond James analyst Andrew Cooper upgraded CareDx to Outperform from Market Perform with a $12 price target. The stock’s risk/reward “skews positive,” the analyst tells investors in a research note. The analyst thinks the worst is behind the company and believes recent signs, such as AlloSure Lung and HeartCare reimbursement from Medicare, show that coverage improvement can still occur.